Elevated B-Type Natriuretic Peptide Is Associated With Increased In-Hospital Mortality or Cardiac Arrest in Patients Undergoing Implantable Cardioverter-Defibrillator Implantation

Background— The implantable cardioverter-defibrillator (ICD) is the most effective treatment for preventing arrhythmic deaths in patients with heart failure, but periprocedural complications, including in-hospital mortality or cardiac arrest, may occur, and little is known about risk factors. We asked whether elevated B-type natriuretic peptide (BNP) level is associated with increased risk of in-hospital mortality or cardiac arrest in patients undergoing ICD implantation. Methods and Results— From the National Cardiovascular Data Registry ICD Registry, we identified 53 198 patients who received ICD implants and underwent preoperative BNP measurement from 2006 to 2008. The patients were categorized into 4 groups by BNP levels (<100, 100 to <300, 300 to <1000, and ≥1000 pg/mL). Complication rates were compared among groups, and odds ratios for in-hospital mortality or cardiac arrest were estimated by multiple hierarchical logistic regressions. There were 2952 complications reported, including 510 in-hospital deaths and 365 cardiac arrests. The rate of in-hospital mortality or cardiac arrest significantly increased with elevated BNP level (P<0.001). The adjusted odds ratios of in-hospital mortality or cardiac arrest were statistically significant in all 3 higher BNP groups [odds ratio (95% CI), 1.99 (1.17 to 3.39), 2.49 (1.50 to 4.13), and 4.25 (2.57 to 7.06) in the second, third, and fourth groups using <100 as reference]. Among subgroups, the association was more significant in men, patients with renal dysfunction, and patients undergoing biventricular ICD implantation. Conclusions— Elevated BNP level was significantly associated with increased risk of in-hospital mortality or cardiac arrest in patients undergoing ICD implant. Strategies aimed at reducing preprocedural BNP or creating systems to manage procedural risk merit further investigation.

[1]  B. Lindsay,et al.  Review of the ICD Registry's third year, expansion to include lead data and pediatric ICD procedures, and role for measuring performance. , 2009, Heart rhythm.

[2]  P. Heidenreich,et al.  Gender Differences in Procedure-Related Adverse Events in Patients Receiving Implantable Cardioverter-Defibrillator Therapy , 2009, Circulation.

[3]  Peter Buser,et al.  BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.

[4]  Karen A. Hartman,et al.  Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. , 2009, Clinical chemistry.

[5]  J. Healey,et al.  Complications associated with defibrillation threshold testing: the Canadian experience. , 2008, Heart rhythm.

[6]  Chunliu Zhan,et al.  Cardiac Device Implantation in the United States from 1997 through 2004: A Population-based Analysis , 2007, Journal of General Internal Medicine.

[7]  A. Maisel,et al.  State-of-the-Art PaperNatriuretic Peptides , 2007 .

[8]  S. Saba,et al.  Effect of End‐Stage Renal Failure and Hemodialysis on Mortality Rates in Implantable Cardioverter‐Defibrillator Recipients , 2007, Pacing and clinical electrophysiology : PACE.

[9]  B. Lindsay,et al.  Review of the registry's first year, data collected, and future plans. , 2007, Heart rhythm.

[10]  D. Cohen,et al.  The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. , 2006, Journal of the American College of Cardiology.

[11]  R. Brindis,et al.  The National ICD Registry: now and into the future. , 2006, Heart rhythm.

[12]  M. Chung,et al.  Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies , 2005, Heart.

[13]  David M. Rocke,et al.  Hierarchical Logistic Regression Modeling with SAS GLIMMIX , 2006 .

[14]  L. Køber,et al.  N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. , 2005, The New England journal of medicine.

[15]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[16]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[17]  H. Huikuri,et al.  Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. , 2004, Journal of the American College of Cardiology.

[18]  A. Kadish,et al.  DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE). , 2003, Cardiac electrophysiology review.

[19]  J. Hollander,et al.  B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  Pedro Lozano.  Natriuretic peptides. , 2020, The Journal of the Arkansas Medical Society.

[21]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[22]  R. Berger,et al.  B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure , 2002, Circulation.

[23]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[24]  A. Coats.  MADIT II, the Multi-center Autonomic Defibrillator Implantation Trial II stopped early for mortality reduction, has ICD therapy earned its evidence-based credentials? , 2002, International journal of cardiology.

[25]  J. Sanderson,et al.  Plasma brain natriuretic peptide — an independent predictor of cardiovascular mortality in acute heart failure , 1999, European journal of heart failure.